Skip To Content
When autocomplete results are available use up and down arrows to review and enter to select. Touch device users, explore by touch or with swipe gestures.
Before it's here, it's on the Bloomberg Terminal.
Learn More
DMCAF:US

DiaMedica Therapeutics Inc

COMPANY INFO
Ticker Change
DMCAF:US has changed to a new ticker symbol
1D1M1Y5Y
View Full Chart
No pricing data is available for this time frame
1D1M1Y5Y
View Full Chart
No pricing data is available for this time frame
markets
Walmart Jumps Most in a Year on Strong 2Q Sales
Before it's here, it's on the Bloomberg Terminal.
Learn More
When autocomplete results are available use up and down arrows to review and enter to select. Touch device users, explore by touch or with swipe gestures.

Key Statistics

P/E Ratio--
Bloomberg (BEst) P/E Ratio--
Bloomberg (BEst) PEG Ratio--
Shares Outstanding--
Price to Book Ratio2.6267
Price to Sales Ratio--
1 Year Return--
30 Day Avg Volume--
EPS--
Bloomberg (BEst) EPS Curr Yr-0.9880
Dividend--
Last Dividend Reported--
Earnings Announcement for Period Ending Q3/2019:11/19/2019

About DiaMedica Therapeutics Inc

DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical company. The Company develops pharmaceutical products for acute ischemic strokes and diabetic kidney disease treatment. DiaMedica Therapeutics offers its services in the United States and Canada.
Address
2 Carlson Parkway Suite 260 Minneapolis, MN 55447 United States
Phone
1-763-496-5454
Website
www.diamedica.com

Income Statement

Quarterly
Annual
;
Q2 2019 (Millions USD)
  • Revenue
    0.00
  • Net Income
    -2,469,000.00
  • Profit Margin
    -104.95%

Balance Sheet

Quarterly
Annual
Q2 2019 (Millions USD)
  • Total Assets
    12.80
  • Total Liabilities
    1.10
  • Debt to Assets
    1.59%

Cash Flow

Quarterly
Annual
Q2 2019 (Millions USD)
  • Operating
    -2.87
  • Investing
    3.01
  • Financing
    0.07